Nigel J Rulewski
Biomedicines
Quintiles Inc., USA
United States of America
Biography
Nigel J Rulewski has 25+ years’ experience in Drug Development and Regulatory Affairs, in both large and small pharma, Venture Capital and Pharmaceutical Business Development. He is presently VP, Strategic Drug Development Group and Head, Biosimilar Center of Excellence, at Quintiles. He has planned the development of biosimilar versions of EPO, GCSF, peg-GCSF, remicade, humira, enbrel, rituximab, avastin and herceptin. He earned his Medical degree at St. Bartholomew’s Medical School, University of London and also holds a Diploma in Child Health, Royal College of Physicians and a Diploma of Royal College of Obstetricians and Gynecologists Nigel J Rulewski has 25+ years’ experience in Drug Development and Regulatory Affairs, in both large and small pharma, Venture Capital and Pharmaceutical Business Development. He is presently VP, Strategic Drug Development Group and Head, Biosimilar Center of Excellence, at Quintiles. He has planned the development of biosimilar versions of EPO, GCSF, peg-GCSF, remicade, humira, enbrel, rituximab, avastin and herceptin. He earned his Medical degree at St. Bartholomew’s Medical School, University of London and also holds a Diploma in Child Health, Royal College of Physicians and a Diploma of Royal College of Obstetricians and Gynecologists
Research Interest
Biosimilars, Biologics, Biomedicines